Your browser doesn't support javascript.
loading
The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes.
Wong, Yao Liang; LeBon, Lauren; Edalji, Rohinton; Lim, Hock Ben; Sun, Chaohong; Sidrauski, Carmela.
Afiliação
  • Wong YL; Calico Life Sciences LLC, South San Francisco, United States.
  • LeBon L; Calico Life Sciences LLC, South San Francisco, United States.
  • Edalji R; Discovery, Global Pharmaceutical Research and Development, AbbVie, North Chicago, United States.
  • Lim HB; Discovery, Global Pharmaceutical Research and Development, AbbVie, North Chicago, United States.
  • Sun C; Discovery, Global Pharmaceutical Research and Development, AbbVie, North Chicago, United States.
  • Sidrauski C; Calico Life Sciences LLC, South San Francisco, United States.
Elife ; 72018 02 28.
Article em En | MEDLINE | ID: mdl-29489452
ABSTRACT
eIF2B is a dedicated guanine nucleotide exchange factor for eIF2, the GTPase that is essential to initiate mRNA translation. The integrated stress response (ISR) signaling pathway inhibits eIF2B activity, attenuates global protein synthesis and upregulates a set of stress-response proteins. Partial loss-of-function mutations in eIF2B cause a neurodegenerative disorder called Vanishing White Matter Disease (VWMD). Previously, we showed that the small molecule ISRIB is a specific activator of eIF2B (Sidrauski et al., 2015). Here, we report that various VWMD mutations destabilize the decameric eIF2B holoenzyme and impair its enzymatic activity. ISRIB stabilizes VWMD mutant eIF2B in the decameric form and restores the residual catalytic activity to wild-type levels. Moreover, ISRIB blocks activation of the ISR in cells carrying these mutations. As such, ISRIB promises to be an invaluable tool in proof-of-concept studies aiming to ameliorate defects resulting from inappropriate or pathological activation of the ISR.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Neuroprotetores / Fator de Iniciação 2B em Eucariotos / Ativadores de Enzimas / Cicloexilaminas / Proteínas Mutantes / Leucoencefalopatias / Acetamidas Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Neuroprotetores / Fator de Iniciação 2B em Eucariotos / Ativadores de Enzimas / Cicloexilaminas / Proteínas Mutantes / Leucoencefalopatias / Acetamidas Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article